What is the recommended apixaban dose for deep vein thrombosis prophylaxis after major orthopedic surgery (hip or knee replacement) and in medically ill patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban Dose for DVT Prophylaxis

For DVT prophylaxis after major orthopedic surgery (hip or knee replacement), use apixaban 2.5 mg orally twice daily, starting 12-24 hours after surgery, for 35 days after hip replacement and 12 days after knee replacement. 1

Major Orthopedic Surgery (Hip and Knee Replacement)

The FDA-approved dosing regimen is straightforward and well-established:

  • Dose: 2.5 mg orally twice daily
  • Initiation: 12-24 hours after wound closure
  • Duration:
    • Hip replacement: 35 days
    • Knee replacement: 12 days 1

This regimen demonstrated superior efficacy compared to enoxaparin 40 mg once daily in the ADVANCE-2 and ADVANCE-3 trials. In hip arthroplasty, apixaban reduced VTE from 3.9% to 1.4% (RR 0.36,95% CI 0.22-0.54, P<0.001), and in knee arthroplasty from 24.4% to 15.1% (RR 0.62,95% CI 0.51-0.78, P<0.0001) 2, 3. Importantly, bleeding rates were numerically lower with apixaban in all trials 2.

The most recent 2025 guidelines confirm apixaban 2.5 mg twice daily as an approved indication for VTE prevention post hip and knee replacements 3. The 2026 ACC statement supports that both DOACs and LMWH are appropriate for VTE prophylaxis post-THA or TKA, with DOACs preferred due to easier logistics and potentially better cost-effectiveness 4.

Important Contraindications and Precautions

Do not use apixaban if:

  • Creatinine clearance < 25 mL/min 3
  • Severe liver disease (Child-Pugh C) 3
  • Concomitant use of potent CYP3A4 inhibitors (ketoconazole, ritonavir) 2

Medically Ill Patients

For acutely ill medical patients, apixaban is NOT recommended for extended thromboprophylaxis. 2

The ADOPT trial evaluated apixaban 2.5 mg twice daily for 30 days versus enoxaparin 40 mg once daily for 6-14 days in hospitalized acutely ill medical patients. The results were disappointing:

  • Efficacy: No superiority over shorter enoxaparin course (2.71% vs 3.06%, RR 0.87,95% CI 0.62-1.23)
  • Safety: Significantly increased major bleeding (0.47% vs 0.19%, RR 2.58,95% CI 1.02-7.24, P<0.04) 2

Therefore, extended thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin and was associated with more bleeding 2. Standard LMWH remains the preferred option for medically ill patients requiring VTE prophylaxis.

Clinical Pearls

  • No dose adjustment needed for age, gender, or body weight in the orthopedic surgery setting 2
  • No bridging required when interrupting apixaban for procedures 5, 1
  • Renal function monitoring is essential—apixaban has 27% renal elimination 2, 3
  • For missed doses, take as soon as possible on the same day; do not double the dose 1

The evidence strongly supports apixaban 2.5 mg twice daily as an effective and safe option for VTE prophylaxis after hip and knee replacement, with a favorable risk-benefit profile compared to traditional LMWH regimens. However, its use in medically ill patients should be avoided due to increased bleeding risk without additional efficacy benefit.

Related Questions

What is the appropriate apixaban (Eliquis) dosing regimen for deep‑vein thrombosis prophylaxis after total hip or knee replacement, including duration, contraindications, and alternative agents?
How soon after hip repair can a patient resume Eliquis (apixaban)?
What is the recommended duration of therapy with Eliquis (apixaban) for indications such as non‑valvular atrial fibrillation, acute deep‑vein thrombosis or pulmonary embolism, and postoperative thromboprophylaxis after hip or knee replacement?
What is the recommended prophylactic dose of apixaban (Eliquis) for preventing venous thromboembolism?
What is the appropriate dose of Eliquis (apixaban) for venous thromboembolism prophylaxis after knee replacement surgery?
What are the first‑line pharmacologic treatments for acute bronchitis and acute bacterial sinusitis in otherwise healthy adults?
When should meropenem be used for typhoid fever and what is the appropriate dosing regimen?
What is the Zuspan regimen for administering magnesium sulfate in eclampsia?
Why has the World Health Organization not commented on the CDC's recommendation to extend oral artemisinin-based combination therapy to five days for uncomplicated malaria?
Which medications can be given to a patient with vertigo and how many rest days should be indicated on a medical certificate?
What is the recommended initial management for a red‑zone Jones fracture (metaphyseal‑diaphyseal junction of the fifth metatarsal) in an active young adult at high risk for non‑union?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.